ERAMET (ER7.DE) Fundamental Analysis & Valuation

FRA:ER7 • FR0000131757

Current stock price

54.6 EUR
+2.65 (+5.1%)
Last:

This ER7.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ER7.DE Profitability Analysis

1.1 Basic Checks

  • In the past year ER7 has reported negative net income.
  • In the past year ER7 has reported a negative cash flow from operations.
  • Of the past 5 years ER7 4 years were profitable.
  • The reported operating cash flow has been mixed in the past 5 years: ER7 reported negative operating cash flow in multiple years.
ER7.DE Yearly Net Income VS EBIT VS OCF VS FCFER7.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of -8.11%, ER7 is doing worse than 81.58% of the companies in the same industry.
  • With a Return On Equity value of -66.43%, ER7 is not doing good in the industry: 92.11% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -8.11%
ROE -66.43%
ROIC N/A
ROA(3y)-2.05%
ROA(5y)1.79%
ROE(3y)-19.55%
ROE(5y)2.47%
ROIC(3y)N/A
ROIC(5y)N/A
ER7.DE Yearly ROA, ROE, ROICER7.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60 -80

1.3 Margins

  • ER7 has a better Gross Margin (63.17%) than 89.47% of its industry peers.
  • In the last couple of years the Gross Margin of ER7 has declined.
  • The Profit Margin and Operating Margin are not available for ER7 so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5Y-1.74%
ER7.DE Yearly Profit, Operating, Gross MarginsER7.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. ER7.DE Health Analysis

2.1 Basic Checks

  • ER7 does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ER7 has less shares outstanding
  • ER7 has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, ER7 has a worse debt to assets ratio.
ER7.DE Yearly Shares OutstandingER7.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
ER7.DE Yearly Total Debt VS Total AssetsER7.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

  • Based on the Altman-Z score of 0.88, we must say that ER7 is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.88, ER7 is doing worse than 81.58% of the companies in the same industry.
  • A Debt/Equity ratio of 3.06 is on the high side and indicates that ER7 has dependencies on debt financing.
  • ER7 has a worse Debt to Equity ratio (3.06) than 92.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.06
Debt/FCF N/A
Altman-Z 0.88
ROIC/WACCN/A
WACC8.86%
ER7.DE Yearly LT Debt VS Equity VS FCFER7.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B

2.3 Liquidity

  • ER7 has a Current Ratio of 1.37. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Current ratio value of 1.37, ER7 is not doing good in the industry: 76.32% of the companies in the same industry are doing better.
  • ER7 has a Quick Ratio of 1.37. This is a bad value and indicates that ER7 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.92, ER7 is doing worse than 65.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 0.92
ER7.DE Yearly Current Assets VS Current LiabilitesER7.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ER7.DE Growth Analysis

3.1 Past

  • ER7 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -3948.08%.
  • The Revenue has decreased by -6.14% in the past year.
  • Measured over the past years, ER7 shows a decrease in Revenue. The Revenue has been decreasing by -0.28% on average per year.
EPS 1Y (TTM)-3948.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-706.79%
Revenue 1Y (TTM)-6.14%
Revenue growth 3Y-18.11%
Revenue growth 5Y-0.28%
Sales Q2Q%-8.91%

3.2 Future

  • ER7 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 32.30% yearly.
  • Based on estimates for the next years, ER7 will show a small growth in Revenue. The Revenue will grow by 1.03% on average per year.
EPS Next Y36.49%
EPS Next 2Y30.76%
EPS Next 3Y32.3%
EPS Next 5YN/A
Revenue Next Year2.81%
Revenue Next 2Y5.29%
Revenue Next 3Y1.03%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ER7.DE Yearly Revenue VS EstimatesER7.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1B 2B 3B 4B 5B
ER7.DE Yearly EPS VS EstimatesER7.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

1

4. ER7.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • ER7 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ER7 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ER7.DE Price Earnings VS Forward Price EarningsER7.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

  • ER7's Enterprise Value to EBITDA ratio is in line with the industry average.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.92
ER7.DE Per share dataER7.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60 80

4.3 Compensation for Growth

  • ER7's earnings are expected to grow with 32.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.76%
EPS Next 3Y32.3%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ER7.DE Dividend Analysis

5.1 Amount

  • ER7 does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ER7.DE Fundamentals: All Metrics, Ratios and Statistics

ERAMET

FRA:ER7 (4/23/2026, 7:00:00 PM)

54.6

+2.65 (+5.1%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)04-23
Earnings (Next)07-28
Inst Owners16.96%
Inst Owner ChangeN/A
Ins Owners0.17%
Ins Owner ChangeN/A
Market Cap1.57B
Revenue(TTM)2.75B
Net Income(TTM)-477.00M
Analysts78
Price Target52.84 (-3.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend1.51
Dividend Growth(5Y)-8.12%
DP-9.01%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-13.96%
PT rev (3m)-4.11%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-784.38%
EPS NY rev (3m)-701.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-4.58%
Revenue NY rev (3m)-4.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.57
P/FCF N/A
P/OCF N/A
P/B 2.19
P/tB 4.26
EV/EBITDA 9.92
EPS(TTM)-16.68
EYN/A
EPS(NY)-6.23
Fwd EYN/A
FCF(TTM)-27.29
FCFYN/A
OCF(TTM)-10.88
OCFYN/A
SpS95.72
BVpS24.97
TBVpS12.83
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -8.11%
ROE -66.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.17%
FCFM N/A
ROA(3y)-2.05%
ROA(5y)1.79%
ROE(3y)-19.55%
ROE(5y)2.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.45%
GM growth 5Y-1.74%
F-Score2
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 3.06
Debt/FCF N/A
Debt/EBITDA 6.58
Cap/Depr 101.29%
Cap/Sales 17.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.37
Quick Ratio 0.92
Altman-Z 0.88
F-Score2
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)258.05%
Cap/Depr(5y)220.45%
Cap/Sales(3y)20.76%
Cap/Sales(5y)16.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3948.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-706.79%
EPS Next Y36.49%
EPS Next 2Y30.76%
EPS Next 3Y32.3%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.14%
Revenue growth 3Y-18.11%
Revenue growth 5Y-0.28%
Sales Q2Q%-8.91%
Revenue Next Year2.81%
Revenue Next 2Y5.29%
Revenue Next 3Y1.03%
Revenue Next 5YN/A
EBIT growth 1Y-237.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5639.65%
EBIT Next 3Y317.49%
EBIT Next 5YN/A
FCF growth 1Y3.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-150.4%
OCF growth 3YN/A
OCF growth 5YN/A

ERAMET / ER7.DE Fundamental Analysis FAQ

What is the fundamental rating for ER7 stock?

ChartMill assigns a fundamental rating of 2 / 10 to ER7.DE.


What is the valuation status of ERAMET (ER7.DE) stock?

ChartMill assigns a valuation rating of 1 / 10 to ERAMET (ER7.DE). This can be considered as Overvalued.


How profitable is ERAMET (ER7.DE) stock?

ERAMET (ER7.DE) has a profitability rating of 2 / 10.


How financially healthy is ERAMET?

The financial health rating of ERAMET (ER7.DE) is 1 / 10.


What is the earnings growth outlook for ERAMET?

The Earnings per Share (EPS) of ERAMET (ER7.DE) is expected to grow by 36.49% in the next year.